Patents by Inventor Luca Andrea Lotta

Luca Andrea Lotta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitors
    Patent number: 11957704
    Abstract: The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: August 31, 2022
    Date of Patent: April 16, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Luca Andrea Lotta, Parsa Akbari, Olukayode Sosina, Manuel Allen Revez Ferreira, Aris Baras
  • Treatment of obesity in subjects having variant nucleic acid molecules encoding Calcitonin Receptor (CALCR)
    Patent number: 11939635
    Abstract: The present disclosure provides methods of treating subjects having obesity and/or increased body mass index (BMI), and methods of identifying subjects having an increased risk of developing obesity and/or BMI.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: March 26, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Luca Andrea Lotta, Parsa Akbari, Manuel Allen Revez Ferreira, Aris Baras
  • Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors
    Patent number: 11891607
    Abstract: The present disclosure provides methods of treating a subject having decreased bone mineral density or at risk of developing decreased bone mineral density, and methods of identifying subjects having an increased risk of developing decreased bone mineral density.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: February 6, 2024
    Assignees: Regeneron Pharmaceuticals, Inc., The Royal Institution For the Advancement of Learning/McGill University
    Inventors: Jonas Bovijn, Olukayode Sosina, Sirui Zhou, Luca Andrea Lotta, Aris Baras, John Brent Richards
  • Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors
    Patent number: 11773393
    Abstract: The present disclosure provides methods of treating subjects having a liver disease, and methods of identifying subjects having an increased risk of developing liver disease.
    Type: Grant
    Filed: March 31, 2022
    Date of Patent: October 3, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Niek Verweij, Luca Andrea Lotta, Aris Baras, Mary Haas, Jonas Nielsen, Olukayode Sosina, Adam Locke
  • Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors
    Patent number: 11759476
    Abstract: The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: September 19, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Luca Andrea Lotta, Parsa Akbari, Olukayode Sosina, Manuel Allen Revez Ferreira, Aris Baras
  • Treatment Of Kidney Diseases With Angiopoietin Like 3 (ANGPTL3) Inhibitors
    Publication number: 20230193271
    Abstract: The present disclosure provides methods of treating a subject having a kidney disease or at risk of developing a kidney disease by administering an Angiopoietin Like 3 (ANGPTL3) inhibitor, and methods of identifying subjects having an increased risk of developing a kidney disease.
    Type: Application
    Filed: December 21, 2022
    Publication date: June 22, 2023
    Inventors: Mary E. Haas, Luca Andrea Lotta, Aris Baras, Manuel Allen Revez Ferreira, Kishor Devalaraja-Narashimha, Lori Morton
  • Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors
    Publication number: 20230172963
    Abstract: The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: August 31, 2022
    Publication date: June 8, 2023
    Inventors: Luca Andrea Lotta, Parsa Akbari, Olukayode Sosina, Manuel Allen Revez Ferreira, Aris Baras
  • Treatment of Liver Diseases With CAMP Responsive Element Binding Protein 3 Like 3 (CREB3L3) Inhibitors
    Publication number: 20230160012
    Abstract: The present disclosure provides methods of treating subjects having a liver disease with a CAMP Responsive Element Binding Protein 3 Like 3 (CREB3L3) inhibitor, and methods of identifying subjects having an increased risk of developing a liver disease.
    Type: Application
    Filed: August 29, 2022
    Publication date: May 25, 2023
    Inventors: Niek Verweij, Luca Andrea Lotta, Aris Baras
  • Methods Of Treating Chronic Kidney Disease (CKD) With Inhibitors Of Protective Loss-Of-Function Genes
    Publication number: 20230107173
    Abstract: The present disclosure provides methods of treating a subject having a kidney disease or preventing a subject from developing a kidney disease, and methods of identifying subjects having an increased risk of developing a kidney disease.
    Type: Application
    Filed: September 22, 2022
    Publication date: April 6, 2023
    Inventors: Mary E. Haas, Luca Andrea Lotta, Aris Baras, Manuel Allen Revez Ferreira, Adam E. Locke, Joshua Backman
  • Treatment of Decreased Bone Mineral Density With Wnt Family Member 5B (WNT5B) Inhibitors
    Publication number: 20230083558
    Abstract: The present disclosure provides methods of treating subjects having decreased bone mineral density or at risk of developing decreased bone mineral density, methods of identifying subjects having an increased risk of developing decreased bone mineral density, methods of detecting Wnt Family Member 5B (WNT5B) variant nucleic acid molecules and variant polypeptides, and WNT5B variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: June 30, 2022
    Publication date: March 16, 2023
    Inventors: Jonas Bovijn, Olukayode Sosina, Luca Andrea Lotta, Aris Baras
  • Methods Of Treating Decreased Bone Mineral Density With Cluster Of Differentiation 109 (CD109) Inhibitors
    Publication number: 20230055912
    Abstract: The present disclosure provides methods of treating a subject having decreased bone mineral density or at risk of developing decreased bone mineral density, and methods of identifying subjects having an increased risk of developing decreased bone mineral density.
    Type: Application
    Filed: July 29, 2022
    Publication date: February 23, 2023
    Inventors: Jonas Bovijn, Okukayode Sosina, Sirui Zhou, Luca Andrea Lotta, Aris Baras, Brent Richards
  • Methods Of Treating Decreased Bone Mineral Density With Kringle Containing Transmembrane Protein 1 (KREMEN1) Inhibitors
    Publication number: 20230021584
    Abstract: The present disclosure provides methods of treating a subject having decreased bone mineral density or at risk of developing decreased bone mineral density, and methods of identifying subjects having an increased risk of developing decreased bone mineral density.
    Type: Application
    Filed: June 30, 2022
    Publication date: January 26, 2023
    Inventors: Jonas Bovijn, Olukayode Sosina, Luca Andrea Lotta, Aris Baras
  • Treatment of Hypertension With Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) Inhibitors
    Publication number: 20230027007
    Abstract: The present disclosure provides methods of treating subjects having hypertension, coronary heart disease, and/or atrial fibrillation or at risk of developing hypertension, coronary heart disease, and/or atrial fibrillation, methods of identifying subjects having an increased risk of developing hypertension, coronary heart disease, and/or atrial fibrillation, and methods of detecting Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: June 30, 2022
    Publication date: January 26, 2023
    Inventors: Manuel Allen Revez Ferreira, Joshua Backman, Alexander Li, Luca Andrea Lotta, Goncalo Abecasis, Aris Baras, Jonas Nielsen
  • Methods Of Treating A Metabolic Disorder With Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15) Inhibitors
    Publication number: 20230025878
    Abstract: The present disclosure provides methods of treating a subject having a metabolic disorder or is at risk of developing a metabolic disorder or preventing a subject from developing a metabolic disorder, and methods of identifying subjects having an increased risk of developing a metabolic disorder.
    Type: Application
    Filed: June 30, 2022
    Publication date: January 26, 2023
    Inventors: Manuel Allen Revez Ferreira, Joshua Backman, Alexander Li, Luca Andrea Lotta, Goncalo Abecasis, Aris Baras
  • Treatment Of Obesity With G-Protein Coupled Receptor 75 (GPR75) Inhibitors
    Publication number: 20220411870
    Abstract: The present disclosure provides methods of treating subjects having obesity, methods of identifying subjects having an increased risk of developing obesity, methods of detecting human G-protein coupled receptor 75 variant nucleic acid molecules and variant polypeptides, and GPR75 variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: May 19, 2022
    Publication date: December 29, 2022
    Inventors: Luca Andrea Lotta, Manuel Allen Revez Ferreira, Aris Baras, Parsa Akbari, Olukayode Sosina
  • Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors
    Publication number: 20220364099
    Abstract: The present disclosure provides methods of treating a subject having a liver disease or type 2 diabetes, and methods of identifying subjects having an increased risk of developing a liver disease or type 2 diabetes.
    Type: Application
    Filed: May 10, 2022
    Publication date: November 17, 2022
    Inventors: Niek Verweij, Olukayode Sosina, Parsa Akbari, Adam Locke, Aris Baras, Luca Andrea Lotta
  • Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors
    Publication number: 20220313726
    Abstract: The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: April 1, 2022
    Publication date: October 6, 2022
    Inventors: Luca Andrea Lotta, Parsa Akbari, Olukayode Sosina, Manuel Allen Revez Ferreira, Aris Baras
  • Treatment Of Liver Disease With Mitochondrial Glycerol-3-Phosphate Acyltransferase (GPAM) Inhibitors
    Publication number: 20220307032
    Abstract: The present disclosure provides methods of treating subjects having liver disease, and methods of identifying subjects having an increased risk of developing liver disease.
    Type: Application
    Filed: February 25, 2022
    Publication date: September 29, 2022
    Inventors: Luca Andrea Lotta, Niek Verweij, Colm O'Dushlaine, Jonathan Marchini, Aris Baras
  • Treatment Of Liver Disease With Ring Finger Protein 213 (RNF213) Inhibitors
    Publication number: 20220307033
    Abstract: The present disclosure provides methods of treating subjects having a liver disease, and methods of identifying subjects having an increased risk of developing a liver disease.
    Type: Application
    Filed: March 1, 2022
    Publication date: September 29, 2022
    Inventors: Luca Andrea Lotta, Niek Verweij, Manuel Allen Revez Ferreira, Aris Baras
  • Treatment of Liver Diseases With Cell Death Inducing DFFA Like Effector B (CIDEB) Inhibitors
    Publication number: 20220282253
    Abstract: The present disclosure provides methods of treating subjects having a liver disease, and methods of identifying subjects having an increased risk of developing liver disease.
    Type: Application
    Filed: March 31, 2022
    Publication date: September 8, 2022
    Inventors: Niek Verweij, Luca Andrea Lotta, Aris Baras, Mary Haas, Jonas Nielsen, Olukayode Sosina, Adam Locke